

# Giovanni Lavorgna

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6074832/publications.pdf>

Version: 2024-02-01

15  
papers

316  
citations

1684188

5  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

706  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Microbiome of the Prostate Tumor Microenvironment. <i>European Urology</i> , 2017, 72, 625-631.	1.9	154
2	Long non-coding RNAs as novel therapeutic targets in cancer. <i>Pharmacological Research</i> , 2016, 110, 131-138.	7.1	71
3	Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. <i>Scientific Reports</i> , 2017, 7, 42157.	3.3	28
4	Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell. <i>Genomics Data</i> , 2015, 3, 4-5.	1.3	25
5	Urine Endocannabinoids as Novel Non-Invasive Biomarkers for Bladder Cancer at Early Stage. <i>Cancers</i> , 2020, 12, 870.	3.7	16
6	A mechanistic insight into the anti-metastatic role of the prostate specific antigen. <i>Translational Oncology</i> , 2021, 14, 101211.	3.7	7
7	Endoplasmic reticulum oxidoreductase 1 alpha modulates prostate cancer hallmarks. <i>Translational Andrology and Urology</i> , 2021, 10, 1110-1120.	1.4	5
8	A virus-free cellular model recapitulates several features of severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 17473.	3.3	4
9	Re: Jinjing Chen, Ilaria Guccini, Diletta Di Mitri, et al. Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer. <i>Nat Genet</i> 2018;50:219-28. <i>European Urology</i> , 2018, 74, e20-e21.	1.9	2
10	Re: Ken J. Kron, Alexander Murison, Stanley Zhou, et al. TMPRSS2-ERG Fusion Co-opts Master Transcription Factors and Activates NOTCH Signaling in Primary Prostate Cancer. <i>Nat Genet</i> 2017;49:1336-45. <i>European Urology</i> , 2018, 73, e106-e107.	1.9	1
11	Re: Exercise and Cancer Treatment: Balancing Patient Needs. <i>Lancet Oncol</i> 2018;19:715. <i>European Urology</i> , 2018, 74, e122-e123.	1.9	1
12	Surnames in Y-Chromosome-related Diseases: A New Tool for the Urologist?. <i>European Urology</i> , 2020, 77, 767-768.	1.9	1
13	Prognostic marker and target in prostate cancer. <i>Aging</i> , 2015, 7, 746-747.	3.1	1
14	Re: Tea's Value as a Cancer Therapy is Steeped in Uncertainty. <i>European Urology</i> , 2019, 76, 706-707.	1.9	0
15	Re: Hung-Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>Eur Urol</i> 2020;77:144-55. <i>European Urology</i> , 2020, 78, e137-e138.	1.9	0